Biocytogen Pharmaceuticals (Beijing) Valuation

Is I54 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of I54 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate I54's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate I54's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for I54?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for I54. This is calculated by dividing I54's market cap by their current preferred multiple.
What is I54's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥2.52b

I54 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.3x
Enterprise Value/EBITDA	196.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does I54's PS Ratio compare to its peers?

The above table shows the PS ratio for I54 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.1x
HPHA Heidelberg Pharma	11.8x	12.3%	€112.3m
FYB Formycon	15.4x	31.8%	€937.6m
BIO3 Biotest	1.3x	-4.1%	€1.3b
2INV 2invest	7.8x	n/a	€60.4m
I54 Biocytogen Pharmaceuticals (Beijing)	3.1x	21.5%	€2.8b

Price-To-Sales vs Peers: I54 is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (9.1x).

Price to Earnings Ratio vs Industry

How does I54's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: I54 is good value based on its Price-To-Sales Ratio (3.1x) compared to the European Biotechs industry average (8.3x).

Price to Sales Ratio vs Fair Ratio

What is I54's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

I54 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.1x
Fair PS Ratio	4.6x

Price-To-Sales vs Fair Ratio: I54 is good value based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst I54 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€0.68	€1.74 +156.0%	10.1%	€1.92	€1.57	n/a	2
Sep ’25	€0.64	€1.74 +174.1%	10.1%	€1.92	€1.57	n/a	2
Aug ’25	€0.65	€1.81 +178.5%	5.4%	€1.91	€1.71	n/a	2
Jul ’25	€0.79	€1.81 +129.6%	5.7%	€1.92	€1.71	n/a	2
Jun ’25	€0.90	€1.81 +102.6%	5.7%	€1.92	€1.71	n/a	2
May ’25	€0.92	€1.81 +97.1%	5.7%	€1.92	€1.71	n/a	2
Apr ’25	€0.81	€2.19 +168.8%	21.5%	€2.66	€1.72	n/a	2
Mar ’25	€0.92	€2.23 +142.2%	19.2%	€2.66	€1.80	n/a	2
Feb ’25	€1.41	€2.23 +58.0%	19.2%	€2.66	€1.80	n/a	2
Jan ’25	n/a	€2.47 0%	5.8%	€2.62	€2.33	n/a	2
Dec ’24	€1.72	€2.55 +48.3%	5.1%	€2.68	€2.42	n/a	2
Nov ’24	€1.16	€2.55 +119.8%	5.1%	€2.68	€2.42	n/a	2
Oct ’24	€1.76	€2.87 +63.0%	19.1%	€3.63	€2.36	n/a	3
Sep ’24	€2.06	€2.87 +39.3%	19.1%	€3.63	€2.36	€0.64	3
Aug ’24	€2.26	€3.49 +54.3%	19.8%	€4.23	€2.57	€0.65	3
Jul ’24	€2.40	€3.95 +64.8%	9.9%	€4.47	€3.53	€0.79	3
Jun ’24	€2.72	€3.95 +45.4%	9.9%	€4.47	€3.53	€0.90	3
May ’24	€2.74	€3.95 +44.3%	9.9%	€4.47	€3.53	€0.92	3
Apr ’24	€2.78	€3.93 +41.4%	9.9%	€4.44	€3.51	€0.81	3
Mar ’24	€3.04	€4.45 +46.4%	16.1%	€5.46	€3.92	€0.92	3
Feb ’24	€2.84	€4.45 +56.7%	16.1%	€5.46	€3.92	€1.41	3
Jan ’24	€2.96	€4.45 +50.4%	16.1%	€5.46	€3.92	n/a	3
Dec ’23	€3.06	€4.62 +50.9%	16.4%	€5.38	€3.86	€1.72	2
Nov ’23	€3.20	€4.92 +53.7%	17.0%	€5.75	€4.08	€1.16	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.